Meeting
2014 ASCO Annual Meeting
Evidence of PIK3CA and TP53 co-mutation in breast cancer identification on next-generation sequencing (NGS) of ERBB2 (HER2)-amplified residual disease following preoperative anti-HER2 therapy.
Authors
Frankie Ann Holmes
Texas Oncology, US Oncology, Houston, TX
Frankie Ann Holmes , Kai Wang , Maren K. Levin , Ying Cao , Gary A. Palmer , Norma Alonzo Palma , Sohail Balasubramanian , Jeffrey S. Ross , Roman Yelensky , Lea Krekow , Kristi McIntyre , Cynthia R. C. Osborne , Joyce O'Shaughnessy
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - HER2/ER
Track
Breast Cancer
Sub Track
HER2+
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 625)
DOI
10.1200/jco.2014.32.15_suppl.625
Abstract #
625
Poster Bd #
89
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
HER3, PI3K, and JAK2 pathway activation on reverse phase protein microarray (RPMA) in HER2-amplified residual disease (RD) refractory to preoperative chemotherapy plus trastuzumab (H), lapatinib (L), or both (HL).
First Author: Frankie Ann Holmes
Poster
2014 ASCO Annual Meeting
Whole-exome sequencing (WES) of HER2+ metastatic breast cancer (MBC) from patients (pts) treated with prior trastuzumab (T): A correlative analysis of TBCRC003.
First Author: Nikhil Wagle
Poster
2013 ASCO Annual Meeting
Use of the FoundationOne next-generation sequencing (NGS) assay to detect actionable alterations leading to clinical benefit of targeted therapies for relapsed and refractory breast cancer.
First Author: Jeffrey S. Ross
Poster
2019 ASCO Annual Meeting
Next-generation sequencing (NGS) results among hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC) patients treated with a CDK4 & 6 inhibitor: A retrospective observational study based on real‑world data.
First Author: Erika Paige Hamilton